Meeting
2017 ASCO Annual Meeting
Response of germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) to hedgehog inhibitor vismodegib.
Authors
Anne S. Tsao
The University of Texas MD Anderson Cancer Center, Houston, TX
Anne S. Tsao , Ignacio Ivan Wistuba , Dianren Xia , Lauren Averett Byers , Lixia Diao , Jing Wang , Vassiliki Papadimitrakopoulou , XiMing Tang , Wei Lu , Humam Kadara , Zeynep H. Gumus , Zhi Tan , Shuxing Zhang , Monique B. Nilsson , John Heymach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9062)
DOI
10.1200/JCO.2017.35.15_suppl.9062
Abstract #
9062
Poster Bd #
388
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A cohort study evaluating the clinical, environmental and genetic profiles of men with early-onset, aggressive prostate cancer.
First Author: Sarah Elizabeth Fenton
Poster
2022 ASCO Annual Meeting
NGS analysis of germline mutation profile of patients with hepatocellular carcinoma in China.
First Author: Xiaobing Wu
Poster
2017 ASCO Annual Meeting
Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.
First Author: Gwo Yaw Ho
Poster
2017 ASCO Annual Meeting
Targeted therapy for non-small cell lung cancer (NSCLC) with HER2, BRAF, or hedgehog alterations: Interim data from MyPathway.
First Author: John D. Hainsworth